Andrew Parece

There has been a considerable amount of attention given to the rising costs of pharmaceutical and biotechnology therapies in the US. In early 2020, Charles River Associates conducted this research to determine what "fair" prices would be for these therapies.

The importance of betting on outcomes, not simply risk sharing, when implementing pharma-payer arrangements. .